Patient Support Services Contact Us
Now Approved
The first and only pegfilgrastim-product autoinjector
Read the press release >

Immuno-oncology Begins Here

Developing immuno-oncology therapies for patients in need

The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.

We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.

About Coherus Immuno-oncology

Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines

Our approved products span multiple therapeutic areas including oncology, immunology and ophthalmology.

See our Products & Pipeline

Latest News

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023